Jul 24th, 2006, 16:15
|
只看该作者 #42 |
|
Senior Member
 
注册日期: Jun 2005
帖子: 2,045
积分:2
精华:2
声望: 281761
  |
imnr coverage: 0.09
Shares up over 5% to a high of $.023 on the Bulletin Boards Monday. Momentum comes as The Immune Response Corporation (OTCBB: IMNR - News) announced today that IncreMental Advantage, an equity research firm, has initiated coverage on the Company with an Accumulate rating, and a price target of $0.09 per share. The Immune Response Corporation's product pipeline has two clinical stage therapeutics in Phase II development, NeuroVax(TM) for multiple sclerosis (MS), and IR103 for HIV/AIDS. The report was issued by IncreMental's highly experienced biotechnology analyst, Robert LeBoyer, who has more than 14 years of Wall Street experience. IncreMental Advantage noted in the report that, "The current market capitalization is only $13.1 million. It is unusual to find such a company with two novel products in Phase II clinical trials." "We believe the Company's clinical programs and valuation justify a market capitalization of $200 million to $225 million. If we divide market valuation by the total number of shares outstanding at this time (current), the valuation is $0.31 to $0.38 per share. Dividing market capitalization by fully diluted shares outstanding gives a valuation of $0.08 to $0.09 per share... When the current stock price is compared with the potential from the company's products, its equity seems almost like a non-expiring option on the trials. We believe these factors make IMNR an undervalued stock," concluded LeBoyer in his report. |
|
|
|
Jul 27th, 2006, 10:16
|
只看该作者 #52 |
|
Senior Member
注册日期: Jun 2005
帖子: 2,045
积分:2
精华:2
声望: 281761
|
Jul 26, 2006 4  00 PMCopyright Business Wire 2006 NEW YORK--(BUSINESS WIRE)--July 26, 2006-- IGIA, Inc., (OTCBB: IGAI), announced today its financial results for the fiscal first quarter ended May 31, 2006, including quarterly revenue of $3,458,885, a 89.5% increase compared to $1,825,208 in revenues for the quarter ended May 31, 2005. Gross profit for the quarter was $2,689,377, a 138.3% increase compared to gross profit of $1,128,721 for the quarter ended May 31, 2005. IGIA, a designer, developer, and worldwide direct marketer and distributor of innovative personal and home care items, significantly increased its purchases of television and Internet advertising to generate the increases in quarterly revenue and gross profit. IGIA's quarterly net income was $16,377,174 or $0.44 per share (basic) and $0.22 per share (diluted), as compared to a net loss of $2,879,886 or $0.16 per share (basic and diluted) for the quarter ended May 31, 2005. Primarily contributing to IGIA's net income was $13,989,024 or $0.37 per share (basic) and $0.19 (diluted) in income realized from the extinguishment of liabilities of IGIA's Tactica International, Inc. subsidiary, in connection with its business restructuring and reorganization plan. Net income also included a $6,091,309 or $0.16 per share (basic) and $0.08 (diluted) unrealized gain resulting from a change in IGIA's common stock value which effects the valuation of securities underlying IGIA's outstanding note and warrant obligations. |
|
|
|
|
Jul 28th, 2006, 00:10
|
只看该作者 #57 |
|
Senior Member
注册日期: Jun 2005
帖子: 2,045
积分:2
精华:2
声望: 281761
|
hbsc.ob on watch. PALO ALTO, CALIFORNIA--(MARKET WIRE)--Jul 27, 2006 -- Human BioSystems ("HBS") (OTC BB:HBSC.OB - News), a developer of preservation platforms for organs and other biomaterials, announced today that it has signed a letter of intent ("LOI") to acquire two ethanol production facility projects from EXL III Group Corporation ("EXL III"), an equity partner in ethanol plant ventures. HBS will also enlist the services of Claude Luster III, the principal of EXL III Group Corporation, to serve as the President of a new subsidiary to be formed to develop the ethanol business. 尾盘放出一定的量。 |
|
|
|
